Alnylam Pharma (ALNY) Misses Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Cuts Price Target on Alnylam Pharma (ALNY) Following 1Q
May 3, 2016 9:40 AM EDTJefferies maintained a Buy rating on Alnylam Pharmaceuticals (NASDAQ: ALNY), and cut the price target to $119.00 (from $122.00), following the company's 1Q earnings report. ALNY reported 1Q16 revenues of $7.3M, ahead of consensus estimates of 7.8M. The company ended the quarter with... More
Leerink Cuts Alnylam (ALNY) PT to $107
May 3, 2016 8:14 AM EDTLeerink Partners analyst, Michael Schmidt, recapped the Alnylam Pharmaceuticals (NASDAQ: ALNY) pipeline update from 1Q results and cut his price target but maintained his Outperform rating. The PT drops to $107 from $120 but still offers 55% upside.
Pipeline updates: (1) Enrollment of the Revusiran Ph III trial in... More
